Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Repatha Gets Price Raise as It Wins Post-Launch Premium for CV Risk Reduction
Amgen Astellas BioPharma’s PCSK9 inhibitor Repatha (evolocumab) will get an NHI price raise in April 2018 as it clinched a post-launch price premium for “true clinical utility” thanks to cardiovascular risk reduction data yielded from its global FOURIER study. Buoyed…
To read the full story
Related Article
- Repatha Label Updated in Japan to Add CV Risk Reduction Data
July 11, 2018
- New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs
March 6, 2018
- Rituxan Biosimilar Price Down 9.5% as Originator Hit by Re-Pricing
March 6, 2018
- Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
- One-Time Blockbusters to Be Re-Priced at 2.5-Times Gx Price Average; Mevalotin, Takepron among the List
March 5, 2018
- 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
- Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
March 5, 2018
- MHLW Unveils New List Prices, Post-Launch Foreign Price Adjustment Applied Only to Opdivo
March 5, 2018
REGULATORY
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
- Japan Backs Calquence-Venclexta Regimen for Untreated CLL via Label Updates
July 22, 2026
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…